Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
about
Mechanisms of intrahepatic triglyceride accumulationValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataCost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsOutcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.Rethinking cost-effectiveness in the era of zero healthcare spending growth.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?The payers' perspective on gene therapies.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.
P2860
Q26773198-B757D0D6-8959-403E-9206-FDBD74ABA6D6Q28072257-F3F66BDC-390D-47A3-952F-0C0CD612C6A2Q28550101-BDAB8A7C-2C40-48FC-9193-EECEA57C7E3AQ35606843-144AAB68-8808-48F2-BA02-258FA9E35D1DQ36155257-885C6647-47C4-44F3-8995-D158318B1BC6Q38470584-EED1E5FA-DFB7-4551-9359-A1A57A57363AQ38566022-2B94F0F4-236E-40C9-9B56-FBE2725A85B3Q38623992-68D1D47A-E9D3-4E0F-BC8A-A1D8ED655C75Q38691333-E05CABAC-000E-4969-A7BF-31B401CE4F2CQ38748387-6EB62152-42EF-4C73-9230-7E5D1A03A5B7Q38755073-5F86F1BB-035D-44E5-903F-9E9EF393510AQ38800572-422F53BE-2F52-4DC6-8736-1CF47C15B2F9Q38932103-59D9C2F8-D5D9-4101-B8B1-7A7E09ADD7FAQ39471203-1C04D2DD-B4CD-4E69-9EDA-199550539EB1Q40562865-E21545DF-B980-4EAC-AF65-0F8E4C899CCDQ42048758-07B35144-0DD4-4415-B915-AEE08850F748Q43095281-00FDFB44-C3D0-4AB0-924C-A80C6482DD3AQ50937941-0EF864C7-A802-43E8-B6F1-CFEAFCBE79CDQ52653977-66119CFC-6DE8-46E3-9A16-A30376170A0AQ55280669-559D7486-A5EF-49CE-8A13-B79AA4DCF561
P2860
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@ast
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@en
type
label
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@ast
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@en
prefLabel
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@ast
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@en
P2860
P356
P1476
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
@en
P2093
P2860
P304
P356
10.1111/JVH.12311
P577
2014-09-15T00:00:00Z